keyword
MENU ▼
Read by QxMD icon Read
search

chronic lymphocytic leukaemia

keyword
https://www.readbyqxmd.com/read/27899414/sentinel-case-of-richter-transformation-from-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-to-cd3-diffuse-large-b-cell-lymphoma
#1
Ali Ismail, Jawed A Mallick, Dahui Qin, Mohammad O Hussaini
AIM: To report the first case of a Richter syndrome where small lymphocytic lymphoma (SLL) progressed to a CD3+ diffuse large B-cell lymphoma (DLBCL). METHODS: Macrodissection of small and large cell lymphomatous components was performed. This was followed by flow cytometric analysis along with molecular B-cell immunoglobulin (heavy and light chains) and T-cell receptor (γ and β chains) gene rearrangement studies to investigate a clonal relationship between the components...
November 29, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27891482/treatment-emergent-agranulocytosis-with-skin-and-gingival-lesions-in-a-chronic-lymphocytic-leukemia-patient-a-case-report
#2
Ramesh Amirisetty, Varun Zade, Meenakshi Boddun, Rolly Gupta, Micky Kumari, Hema Suryawanshi
Chronic Lymphocytic Leukaemia (CLL) is a monoclonal lymphoid malignancy characterized by progressive accumulation of small, mature but functionally incompetent neoplastic lymphocytes in the peripheral blood, bone marrow and lymphoid organs. Patients present a variable course and may not require early intervention unlike other malignancies. Patients with rapidly deteriorating blood counts, and organomegaly need treatment. Alkylating agent live Bendamustine combined with Rituximab, anti-CD 20 monoclonal antibody have shown promising results in such patients...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27885078/the-international-nuclear-workers-study-inworks-a-collaborative-epidemiological-study-to-improve-knowledge-about-health-effects-of-protracted-low-dose-exposure
#3
Dominique Laurier, David B Richardson, Elisabeth Cardis, Robert D Daniels, Michael Gillies, Jackie O'Hagan, Ghassan B Hamra, Richard Haylock, Klervi Leuraud, Monika Moissonnier, Mary K Schubauer-Berigan, Isabelle Thierry-Chef, Ausrele Kesminiene
INWORKS is a multinational cohort study, gathering 308 297 workers in the nuclear industry in France, the United Kingdom and the United States of America, with detailed individual monitoring data for external exposure to ionising radiation. Over a mean duration of follow-up of 27 y, the number of observed deaths was 66 632, including 17 957 deaths due to solid cancers, 1791 deaths due to haematological cancers and 27 848 deaths due to cardiovascular diseases. Mean individual cumulative external dose over the period 1945-2005 was 25 mSv...
November 24, 2016: Radiation Protection Dosimetry
https://www.readbyqxmd.com/read/27862308/alemtuzumab-consolidation-in-chronic-lymphocytic-leukaemia-a-phase-i-ii-multicentre-trial
#4
Othman Al-Sawaf, Kirsten Fischer, Carmen D Herling, Matthias Ritgen, Sebastian Böttcher, Jasmin Bahlo, Thomas Elter, Stephan Stilgenbauer, Barbara F Eichhorst, Raymonde Busch, Ute Elberskirch, Wolfgang Abenhardt, Michael Kneba, Michael Hallek, Clemens-Martin Wendtner
OBJECTIVE: Despite high rates of long-lasting remissions in patients with chronic lymphocytic leukaemia (CLL) treated with chemoimmunotherapy, none of the current therapeutic approaches is curative with the exception of allogeneic transplantation. One strategy to extend progression-free survival and long-term survival might be the establishment of consolidation therapies. METHODS: In this trial, patients with complete or partial second remission after fludarabine-based treatment received consolidation therapy with alemtuzumab...
November 9, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27861736/real-world-clinical-experience-in-the-connect-%C3%A2-chronic-lymphocytic-leukaemia-registry-a-prospective-cohort-study-of-1494-patients-across-199-us-centres
#5
Anthony Mato, Chadi Nabhan, Neil E Kay, Mark A Weiss, Nicole Lamanna, Thomas J Kipps, David L Grinblatt, Ian W Flinn, Mark F Kozloff, Christopher R Flowers, Charles M Farber, Pavel Kiselev, Arlene S Swern, Kristen Sullivan, E Dawn Flick, Jeff P Sharman
The clinical course of chronic lymphocytic leukaemia (CLL) is heterogeneous, and treatment options vary considerably. The Connect(®) CLL registry is a multicentre, prospective observational cohort study that provides a real-world perspective on the management of, and outcomes for, patients with CLL. Between 2010 and 2014, 1494 patients with CLL and that initiated therapy, were enrolled from 199 centres throughout the USA (179 community-, 17 academic-, and 3 government-based centres). Patients were grouped by line of therapy at enrolment (LOT)...
November 8, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27858991/management-of-central-nervous-system-involvement-in-chronic-lymphocytic-leukaemia-a-retrospective-cohort-of-30-patients
#6
Anne Wanquet, Rudy Birsen, Charlotte Bonnet, Marouane Boubaya, Sylvain Choquet, Jehan Dupuis, Stephane Lepretre, Daniel Re, Jonathan Fahri, Anne-Sophie Michallet, Loïc Ysebaert, Richard Lemal, Thierry Lamy, Richard Delarue, Xavier Troussard, Florence Cymbalista, Vincent Levy, Pierre-Yves Dietrich, Veronique Leblond, Therese Aurran-Schleinitz
Central nervous system involvement (CNSi) is a rare and poorly reported complication of chronic lymphocytic leukaemia (CLL). Establishing cause and effect between the CLL and the neurological symptoms remains challenging. We have analysed a retrospective cohort of 30 CLL patients with CNSi, documented by lymphocytic infiltration either by flow cytometry of the cerebrospinal fluid (CSF; n = 29) or CNS biopsy (n = 1). Neurological symptoms were heterogeneous. At the time of CNSi, less than half of the patients had a progressive CLL and 20 had never been treated for CLL...
November 11, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27855324/green-tea-polyphenol-epigallocatechin-3-gallate-differentially-induces-apoptosis-in-cll-b-and-t-cells-but-not-in-healthy-b-and-t-cells-in-a-dose-dependant-manner
#7
Scott Cornwall, Gavin Cull, David Joske, Reza Ghassemifar
B-cell chronic lymphocytic leukaemia (CLL) is characterized by an accumulation of CD5-positive monoclonal B-cells due in large part to a failure of apoptosis. The ability to study CLL B-cells in vitro has always been a challenge and hampered by the low viability of the CLL B-cells in cell culture systems. In this study, we present a multicellular cell culture system to maintain CLL B-cells viable in culture for 60h in the presence of a stromal cell feeder layer in combination with a whole white blood cell preparation...
November 2, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27822100/the-danish-national-chronic-lymphocytic-leukemia-registry
#8
REVIEW
Caspar da Cunha-Bang, Christian Hartmann Geisler, Lisbeth Enggaard, Christian Bjørn Poulsen, Peter de Nully Brown, Henrik Frederiksen, Olav Jonas Bergmann, Elisa Jacobsen Pulczynski, Robert Schou Pedersen, Linda Højberg Nielsen, Ilse Christiansen, Carsten Utoft Niemann
AIM: In 2008, the Danish National Chronic Lymphocytic Leukemia Registry was founded within the Danish National Hematology Database. The primary aim of the registry is to assure quality of diagnosis and care of patients with chronic lymphocytic leukemia (CLL) in Denmark. Secondarily, to evaluate adherence to national guidelines and to provide source data for research purposes. STUDY POPULATION: All patients diagnosed with CLL in Denmark from 2008 onward are included in the registry...
2016: Clinical Epidemiology
https://www.readbyqxmd.com/read/27808110/structural-characterisation-of-high-affinity-siglec-2-cd22-ligands-in-complex-with-whole-burkitt-s-lymphoma-bl-daudi-cells-by-nmr-spectroscopy
#9
Paul D Madge, Andrea Maggioni, Mauro Pascolutti, Moein Amin, Mario Waespy, Bernadette Bellette, Robin J Thomson, Sørge Kelm, Mark von Itzstein, Thomas Haselhorst
Siglec-2 undergoes constitutive endocytosis and is a drug target for autoimmune diseases and B cell-derived malignancies, including hairy cell leukaemia, marginal zone lymphoma, chronic lymphocytic leukaemia and non-Hodgkin's lymphoma (NHL). An alternative to current antibody-based therapies is the use of liposomal nanoparticles loaded with cytotoxic drugs and decorated with Siglec-2 ligands. We have recently designed the first Siglec-2 ligands (9-biphenylcarboxamido-4-meta-nitrophenyl-carboxamido-Neu5Acα2Me, 9-BPC-4-mNPC-Neu5Acα2Me) with simultaneous modifications at C-4 and C-9 position...
November 3, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27789740/the-mutational-signature-of-chronic-lymphocytic-leukemia
#10
REVIEW
Helen Parker, Jonathan C Strefford
Advances in next-generation sequencing technologies continue to unravel the cancer genome, identifying key biological pathways important for disease pathogenesis and clinically relevant genetic lesions. These studies have provided unprecedented resolution of the cancer genome, facilitating significant advances in the ability to detect many cancers, and predict patients who will develop an aggressive disease or respond poorly to treatment. The mature B-cell neoplasm chronic lymphocytic leukaemia remains at the forefront of these genomic analyses, largely due its protracted natural history and the accessibility to suitable material for study...
November 1, 2016: Biochemical Journal
https://www.readbyqxmd.com/read/27773210/evaluation-of-snp-microarray-based-chromosome-testing-for-detection-of-prognostically-relevant-genomic-abnormalities-in-chronic-lymphocytic-leukaemia
#11
Melody Caramins, Nicole Chia, Stephen Mulligan
No abstract text is available yet for this article.
February 2016: Pathology
https://www.readbyqxmd.com/read/27773070/serum-from-a-subset-of-patients-with-chronic-lymphocytic-leukaemia-and-large-local-reactions-to-mosquito-bites-significantly-induces-upregulation-of-cd63-surface-expression-in-atopic-basophils
#12
Jamma Li, Oliver G Best, Stephen P Mulligan, Suran L Fernando
No abstract text is available yet for this article.
February 2016: Pathology
https://www.readbyqxmd.com/read/27773034/exploring-the-mechanisms-of-large-local-reactions-to-insect-bites-in-patients-with-chronic-lymphocytic-leukaemia
#13
Jamma Li, Oliver G Best, Stephen P Mulligan, Suran L Fernando
No abstract text is available yet for this article.
February 2016: Pathology
https://www.readbyqxmd.com/read/27756834/ibrutinib-for-relapsed-refractory-chronic-lymphocytic-leukemia-a-uk-and-ireland-analysis-of-outcomes-in-315-patients
#14
(no author information available yet)
In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukemia patients. The UK Chronic Lymphocytic Leukaemia Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints; the number of patients still on therapy at 1 year "discontinuation-free survival" and 1 year overall survival. With a median of 16 months follow up, data on 315 patients demonstrated a 1 year discontinuation-free survival of 73.7% and a 1 year overall survival of 83...
December 2016: Haematologica
https://www.readbyqxmd.com/read/27748757/increased-fc%C3%AE-riib-dominance-contributes-to-the-emergence-of-resistance-to-therapeutic-antibodies-in-chronic-lymphocytic-leukaemia-patients
#15
M Burgess, S Mapp, R Mazzieri, C Cheung, L Chambers, S R Mattarollo, P Mollee, D Gill, N A Saunders
Resistance to therapeutic antibodies in chronic lymphocytic leukaemia (CLL) is common. In this study, we show that therapeutic antibodies against CD62L (CD62L-Ab) or CD20 (obinutuzumab) were able to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADP) in primary cultures of CLL cells. CLL cells derived from patients with active disease requiring treatment displayed resistance to these antibodies, whereas patients with stable disease were sensitive. Using enrichment strategies and transcriptomic analyses, we show that antibody-dependent tumour cell killing was FcγR-dependent and mediated by macrophages...
October 17, 2016: Oncogene
https://www.readbyqxmd.com/read/27746042/rituximab-in-lymphoma-and-chronic-lymphocytic-leukaemia-a-practice-guideline
#16
A Prica, F Baldassarre, L K Hicks, K Imrie, T Kouroukis, M Cheung
Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aimed to systematically review and update the literature on rituximab in lymphoma and CLL, and provide evidence-based consensus guidelines for its rational use. Validated methodology from the Cancer Care Ontario Program in Evidence-based Care was used. A comprehensive literature search was completed by a methodologist from the Hematology Disease Site Group of Cancer Care Ontario...
October 13, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27742073/genetic-evolution-in-chronic-lymphocytic-leukaemia
#17
Julio Delgado, Neus Villamor, Armando López-Guillermo, Elías Campo
Next-generation sequencing provides a comprehensive understanding of the genomic, epigenomic and transcriptomic underpinnings of chronic lymphocytic leukaemia. Recent studies have uncovered new drivers, including mutations in non-coding regions, and signalling pathways whose role in cancer was previously unknown or poorly understood. Moreover, massive scale epigenomics and transcriptomics have supplied the foundations for the cellular origin of the disease. Some drivers could be targeted pharmacologically, and the ability to detect mutations present in minority subclones might even allow treatment before clonal selection occurs, thus preventing disease refractoriness...
March 2016: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/27742066/the-21st-century-revolution-in-cll-why-this-matters-to-patients
#18
Brian Koffman, Andrew Schorr
The 21st century has seen rapid, positive changes in the management of chronic lymphocytic leukaemia from the patient's perspective. New prognostic and predictive markers have ushered in the start of more precise and individualized therapy. For the first time, combined therapy [fludarabine, cyclophosphamide and rituximab] has been shown to prolong life significantly. Clinical trials have become more adaptive, faster and more patient friendly. Perhaps the greatest change of all is the development of novel oral agents (ibrutinib and idelalisib) and powerful monoclonal antibodies that offer robust and durable disease control...
March 2016: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/27742064/present-and-future-of-personalized-medicine-in-cll
#19
Emili Montserrat, Tycho Bauman, Julio Delgado
Medicine has been 'personalized' (i.e. centred in persons) since its foundation. Recently, however, the term 'personalized medicine' (or, better, 'precision medicine') has been introduced to define 'a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease'. This concept has gained momentum thanks to next-generation-sequencing (NGS) techniques that allow identification of molecular characteristics unique to the patient and to the tumour...
March 2016: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/27717146/hyperdiploidy-as-a-rare-event-that-accompanies-poor-prognosis-markers-in-cll
#20
Isabel González-Gascón Y Marín, Ana África Martín, María Hernández-Sanchez, Cristina Robledo, María Lourdes Hermosín, Natalia de Las Heras, Laura Lacalle, Josefina Galende, Felipe de Arriba, Ana Eugenia Rodríguez-Vicente, José-Ángel Hernández, Jesús María Hernández-Rivas
: The presence of chromosomal gains other than trisomy 12 in chronic lymphocytic leukaemia (CLL) is unusual. However, some patients may show gains on several chromosomes simultaneously suggesting a hyperdiploid karyotype. OBJECTIVE: The objective of this study was to analyse by FISH the frequency and prognostic impact of hyperdiploidy in CLL. METHOD: A review of 1359 consecutive cases diagnosed with CLL referred for FISH analysis to a unique institution was carried out...
September 26, 2016: European Journal of Haematology
keyword
keyword
68560
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"